ArticleRadiation oncology (London, England)2025
A nomogram predicting prognosis of extensive-stage small cell lung cancer patients receiving chemoradiotherapy.
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo identify the prognostic factors for extensive-stage small cell lung cancer (ES-SCLC) patients after chemoradiotherapy and to develop an effective nomogram for predicting overall survival (OS).
methodData of ES-SCLC patients who received chemoradiotherapy from 2010 to 2020 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. For intergroup analysis, data were clustered into train and test sets at random (ratio: 7:3). Cox proportional hazards model and stepwise regression were used to identify independent risk factors for OS and to construct a prognostic nomogram. The nomogram’s performance was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA), and compared with the American Joint Committee on Cancer (AJCC) TNM (Tumor-Node-Metastasis) staging system. Risk stratification was performed using X-tile software. Kaplan-Meier survival curves were plotted to compare outcomes. An independent external validation cohort (N = 100) was used to further verify the model.
results1,336 ES-SCLC patients were included (train set: 935; test set: 401). Multivariate Cox regression analysis uncovered that being male, age over 74 years, liver metastasis, bilateral laterality, brain metastasis, bone metastasis, N3 stage, and tumor size between 28 and 80 mm and over 80 mm were independent risk factors (P < 0.05) for ES-SCLC patients receiving chemoradiotherapy. In comparison with the TNM staging, the nomogram demonstrated superior predictive ability for 1-year, 3-year, and 5-year survival in both the train set (AUC: 0.69 vs. 0.53, 0.74 vs. 0.57, 0.79 vs. 0.62) and the test set (AUC: 0.67 vs. 0.55, 0.79 vs. 0.63, 0.82 vs. 0.70). Furthermore, it exhibited robust performance in the external validation cohort (1-, 3-, 5-year AUC: 0.75, 0.78, 0.76). Calibration curves indicated good agreement with the diagonal. DCA results demonstrated a positive net benefit. Patients with low risk (< 204 points) had better survival outcomes than those with medium risk (204–229 points) and high risk (> 229 points) (P < 0.0001).
conclusionWe constructed and validated a nomogram that effectively predicts survival in ES-SCLC patients after chemoradiotherapy, which could assist clinicians in devising more precise and individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.